The Possible Impact of Montelukast in Parkinson’s Disease: A Substantial Contribution

Areej Turkistani, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Duaa Eliwa, Athanasios Alexiou, Hala Alnoaman, Marios Papadakis, Gaber El-Saber Batiha, Department of Pharmacology and Toxicology, Collage of Medicine, Taif University, Kingdom of Saudi Arabia, Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Jabir ibn Hayyan Medical University, Department of Pharmacognosy, Faculty of Pharmacy, Tanta University, European Academy of Sciences and Arts, University Centre for Research , Chandigarh University, Consultant Family Medicine Ministry of Health, Kingdom of Saudi Arabia, Medical Department, Faculty of Life Sciences, University of Thessaly, Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhur University

Journal of Geriatric Psychiatry and Neurology

Published online on January 13, 2026

Abstract

Journal of Geriatric Psychiatry and Neurology, Ahead of Print.
Background:Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by α-synuclein aggregation and dopaminergic neuron degeneration in the substantia nigra. Evidence suggests that the leukotriene (LT) pathway contributes to PD ...